Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer-Reference-Cited by-同舟云学术

Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer

Published:2017-06-16 Issue:9 Volume:6 Page:e1339856
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Kaderbhai Courèche-Guillaume¹²,Richard Corentin²³,Fumet Jean David¹²,Aarnink Anne¹,Ortiz-Cuaran Sandra⁴,Pérol Maurice⁴,Foucher Pascal⁵,Coudert Bruno¹,Favier Laure¹,Lagrange Aurélie¹,Limagne Emeric²³,Boidot Romain²³,Ladoire Sylvain¹²,Poudenx Michel⁶,Ilie Marius⁷⁸⁹,Hofman Paul⁷⁸⁹,Saintigny Pierre⁴,Ghiringhelli François¹²³

Affiliation:

1. Department of Medical Oncology, Center GF Leclerc, Dijon, France

2. Plateform Transfer in Biological Oncology, Dijon, France

3. GIMI Genetic and Immunology Medical Institute, Dijon, France

4. Department of Medical Oncology, Center Leon Berard, Lyon, France

5. Department of Thoracic Oncology CHU, Dijon, France

6. Department of Pulmonary Oncology, Antoine Lacassagne Comprehensive Cancer Center, FHU OncoAge, Nice, France

7. Laboratory of Clinical and Experimental Pathology, FHU OncoAge, CHU de Nice, Université Côte d'Azur, Nice, France

8. Institute for Research on Cancer and Ageing, Nice (IRCAN), INSERM U1081/UMR CNRS 7284, FHU OncoAge, Université Côte d'Azur, Nice, France

9. Hospital-Integrated Biobank (BB-0033–00025), FHU OncoAge, CHU de Nice, Université Côte d'Azur, Nice, France

Publisher

Informa UK Limited